CA2912052C - Lipid scavenging in ras cancers - Google Patents

Lipid scavenging in ras cancers Download PDF

Info

Publication number
CA2912052C
CA2912052C CA2912052A CA2912052A CA2912052C CA 2912052 C CA2912052 C CA 2912052C CA 2912052 A CA2912052 A CA 2912052A CA 2912052 A CA2912052 A CA 2912052A CA 2912052 C CA2912052 C CA 2912052C
Authority
CA
Canada
Prior art keywords
ras
cells
fatty acids
lipid
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2912052A
Other languages
English (en)
French (fr)
Other versions
CA2912052A1 (en
Inventor
Joshua Rabinowitz
Jurre KAMPHORST
Justin CROSS
Craig Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Princeton University
Memorial Sloan Kettering Cancer Center
Original Assignee
Princeton University
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Princeton University, Memorial Sloan Kettering Cancer Center filed Critical Princeton University
Priority to CA3136947A priority Critical patent/CA3136947C/en
Publication of CA2912052A1 publication Critical patent/CA2912052A1/en
Application granted granted Critical
Publication of CA2912052C publication Critical patent/CA2912052C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2912052A 2013-05-10 2014-05-09 Lipid scavenging in ras cancers Active CA2912052C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3136947A CA3136947C (en) 2013-05-10 2014-05-09 Lipid scavenging in ras cancers

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361822095P 2013-05-10 2013-05-10
US61/822,095 2013-05-10
PCT/US2014/037514 WO2014183047A1 (en) 2013-05-10 2014-05-09 Lipid scavenging in ras cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3136947A Division CA3136947C (en) 2013-05-10 2014-05-09 Lipid scavenging in ras cancers

Publications (2)

Publication Number Publication Date
CA2912052A1 CA2912052A1 (en) 2014-11-13
CA2912052C true CA2912052C (en) 2021-12-14

Family

ID=51867773

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2912052A Active CA2912052C (en) 2013-05-10 2014-05-09 Lipid scavenging in ras cancers
CA3136947A Active CA3136947C (en) 2013-05-10 2014-05-09 Lipid scavenging in ras cancers

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3136947A Active CA3136947C (en) 2013-05-10 2014-05-09 Lipid scavenging in ras cancers

Country Status (7)

Country Link
US (2) US10130600B2 (enExample)
EP (1) EP2993980B1 (enExample)
JP (2) JP6533519B2 (enExample)
AU (3) AU2014262450A1 (enExample)
CA (2) CA2912052C (enExample)
IL (2) IL242492B (enExample)
WO (1) WO2014183047A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
CA2725978A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
US8669057B2 (en) 2009-05-07 2014-03-11 Veracyte, Inc. Methods and compositions for diagnosis of thyroid conditions
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
US10513737B2 (en) 2011-12-13 2019-12-24 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
ES3015226T3 (en) 2012-08-16 2025-04-30 Veracyte Sd Inc Prostate cancer prognosis using biomarkers
WO2014186036A1 (en) 2013-03-14 2014-11-20 Allegro Diagnostics Corp. Methods for evaluating copd status
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
EP2993980B1 (en) 2013-05-10 2023-11-01 Memorial Sloan Kettering Cancer Center Lipid scavenging in ras cancers
US11369588B2 (en) 2014-03-20 2022-06-28 The Trustees Of Princeton University NADPH production by the 10-formyl-THF pathway, and its use in the diagnosis and treatment of disease
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
CN114606309A (zh) 2014-11-05 2022-06-10 威拉赛特公司 使用机器学习和高维转录数据的诊断系统和方法
US11414708B2 (en) 2016-08-24 2022-08-16 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
AU2018210695B2 (en) 2017-01-20 2024-07-18 The University Of British Columbia Molecular subtyping, prognosis, and treatment of bladder cancer
WO2018165600A1 (en) 2017-03-09 2018-09-13 Genomedx Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
US11078542B2 (en) 2017-05-12 2021-08-03 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
AU2018310987A1 (en) 2017-08-04 2020-02-27 Decipher Biosciences, Inc. Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07509470A (ja) * 1992-07-24 1995-10-19 ザ・ジョーンズ・ホプキンス・ユニバーシティ がんの治療に脂肪酸合成阻害剤を用いる方法
US6156504A (en) 1996-03-15 2000-12-05 The Penn State Research Foundation Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays
US6214875B1 (en) * 1998-04-14 2001-04-10 Zhenhua Yang Anticancer effects of specific branched-chain fatty acids and related production process
CA2519773C (en) 2003-03-27 2014-02-18 Kengo Akimoto Lipid-improving agent and composition containing lipid-improving agent
US8092839B2 (en) * 2004-12-13 2012-01-10 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer and other diseases
US8652508B2 (en) * 2007-05-25 2014-02-18 Children's Medical Center Corporation Dietary formulations and methods for treatment of inflammation and other disorders
US20100129430A1 (en) * 2008-11-24 2010-05-27 Stavroula Sofou Liposome drug carriers with ph-sensitivity
TWI629992B (zh) 2011-05-27 2018-07-21 明治股份有限公司 用於預防以及／或者改善癌症引起的非可逆性的代謝紊亂的組合物
RS56394B1 (sr) * 2011-06-15 2017-12-29 Stable Solutions Llc Terapeutska primena parenteralnog kril ulja
EP2993980B1 (en) 2013-05-10 2023-11-01 Memorial Sloan Kettering Cancer Center Lipid scavenging in ras cancers

Also Published As

Publication number Publication date
EP2993980A1 (en) 2016-03-16
IL282229A (en) 2021-05-31
IL242492B (en) 2021-04-29
AU2018201800B2 (en) 2020-10-22
US20160120832A1 (en) 2016-05-05
US20190046489A1 (en) 2019-02-14
EP2993980A4 (en) 2017-04-19
IL282229B1 (en) 2023-01-01
CA3136947C (en) 2023-08-08
WO2014183047A1 (en) 2014-11-13
JP6533519B2 (ja) 2019-06-19
AU2014262450A1 (en) 2015-12-03
JP6970709B2 (ja) 2021-11-24
AU2018201800C1 (en) 2021-04-22
AU2018201800A1 (en) 2018-04-05
AU2021200360A1 (en) 2021-03-18
JP2016521286A (ja) 2016-07-21
JP2019147836A (ja) 2019-09-05
US10772862B2 (en) 2020-09-15
CA2912052A1 (en) 2014-11-13
IL282229B2 (en) 2023-05-01
EP2993980B1 (en) 2023-11-01
CA3136947A1 (en) 2014-11-13
US10130600B2 (en) 2018-11-20

Similar Documents

Publication Publication Date Title
US10772862B2 (en) Lipid scavenging in Ras cancers
Walczak et al. Kynurenic acid and cancer: facts and controversies
Kita et al. Probiotic-derived ferrichrome inhibits the growth of refractory pancreatic cancer cells
Kang et al. Deficiency of BCAT2-mediated branched-chain amino acid catabolism promotes colorectal cancer development
Bernfeld et al. Phospholipase D–dependent mTOR complex 1 (mTORC1) activation by glutamine
JP2019507754A (ja) 少なくとも２つの非必須アミノ酸を欠くダイエタリー製品
Peng et al. KHK-A promotes fructose-dependent colorectal cancer liver metastasis by facilitating the phosphorylation and translocation of PKM2
Zhao et al. Glycolytic inhibition with 3-bromopyruvate suppresses tumor growth and improves survival in a murine model of anaplastic thyroid cancer
US20100022495A1 (en) Modulating endoplasmic reticulum stress in the treatment of tuberous sclerosis
Duan et al. The potential role of reprogrammed glucose metabolism: an emerging actionable codependent target in thyroid cancer
US20260076954A1 (en) Compositions and methods for reducing cancer stem cells
Wang et al. Acid-sensing ion channel 1: potential therapeutic target for tumor
Hashimoto et al. Orchestration of mesenchymal plasticity and immune evasiveness via rewiring of the metabolic program in pancreatic ductal adenocarcinoma
US20150290168A1 (en) Class iia hdac inhibitors for the treatment of infection
Xu et al. Combined BRAF and PIM1 inhibitory therapy for papillary thyroid carcinoma based on BRAFV600E regulation of PIM1: Synergistic effect and metabolic mechanisms
Ding et al. Glutamine and cancer: metabolism, immune microenvironment, and therapeutic targets
Elkabets et al. Pharmacological activation of SIRT6 suppresses progression of head and neck and esophagus squamous cell carcinoma by modulation of cellular metabolism and protein translation
Li et al. PPDPF promotes esophageal squamous cell carcinoma progression by blocking PCCA binding to PCCB and inhibiting methionine catabolism
Zhang et al. Myricetin alleviates hepatic ischemia-reperfusion injury in mice by inhibiting the inflammatory response and ferroptosis through farnesoid X receptor (FXR)
Schoonjans Tumor microenvironment involvement in the metabolic reprogramming induced by the PDK inhibitor dichloroacetate
Al-Asadi Preventing and Treating Hepatic Metastases of Colon and Pancreatic Cancers by Targeting Cancer Cell Metabolism
CN121221774A (zh) 一种基于dgat1靶点的胰腺癌免疫治疗药物及应用
Gabra Adaptations to Glutamine Deprivation in Cancer and Its Use as a Dietary Supplement in Cancer Therapeutics
Nakamura et al. Su1250 Glucagon-Like Peptide-1 Does Not Enhance Inflammatory Responses in Pancreatic Stellate Cells, but Induces Cell Proliferation via ERK Pathway
Kim Simultaneously inhibiting multiple nutrient acquisition pathways using synthetic sphingolipid compounds

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190507

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250318

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250318